Abstract
Bevacizumab-based chemotherapy is the recommended first-line therapeutic strategy for metastatic colorectal cancer (mCRC). Yet, some patients do not benefit from this association and until now robust predictive or prognostic biomarker with clinical practice applicability have not been identified. Serum analysis by mid-infrared spectroscopy (SMIRS) allows a rapid and non-invasive metabolomic profiling of an individual. Its prognostic value has never been assessed in mCRC. The aim of this study was to evaluate the prognostic yield of SMIRS in patients receiving first-line bevacizumab-based treatment for mCRC.
Full Text
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call